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3,2 Proenzymes, Bnzymes, Inhibitors,
Cofactors
3.2.1 Blood Coagulation Factors II, V, VII, VIII, IX, X
and XI:
Determination by Clotting Assays
Maria C. E. van Dam-Mieras. Annemarie D. Muller and
H. Coenraad Hemker
General
When a blood vessel is damaged the bleeding is stopped by the combined action of the
vessel wall, thrombocytes and blood coagulation enzymes. The blood coagulation
enzymes occur in plasma as inactive precursors and can become activated in a series of
consecutive reactions, some of which take place at lipid/water interfaces. In this reac-
tion sequence the product of the first reaction functions as the enzyme in the second
reaction, the product of the second reaction functions as the enzyme in the third reac-
tion, and so on. This so-called coagulation cascade is depicted in Fig. 1.
The classical concept of an intrinsic pathway of coagulation, triggered by the expo-
sure of blood to non-endothelial surfaces, and an extrinsic pathway of coagulation,
initiated by the interaction of factor VII with tissue thromboplastin, joining at the
factor X activation step (bold lines in Fig. 1) has been shown to be an oversimplifica-
tion [1,2]. Recent research has shown that the initiating reactions of both pathways
are intimately linked (dotted lines in Fig. 1).
As can be seen in Fig. 1, the reactions in which the vitamin K-dependent coagula-
tion factors (II, VII, IX and X) participate proceed at lipid/water interfaces. The effi-
ciency of the reactions catalyzed by the vitamin K-dependent coagulation factors can
be regulated through manipulation of their affinity to lipid/water interfaces. Oral
anticoagulation therapy is based on this principle.
The ordered and controlled interplay of the coagulation cascade reactions is accom-
plished by the high degree of specificity of the coagulation enzymes and by a system of
positive and negative feedback mechanisms. The majority of coagulation factors are
serine proteases; only the factors Vu and VIII. do not possess intrinsic enzymatic
activity, but they form complexes with the factors X" and IXu, respectively, thereby
markedly stimulating the activities of the latter enzymes by acting as cofactors or
accelerators.
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Fig. l. The blood coagulation cascade, schematic. Possible interrelations between the intrinsic and extrinsic
pathways are indicated by dashed lines. PL : phospholipid.
The ultimate visible effect of coagulation is the conversion of soluble fibrinogen
into insoluble fibrin by thrombin. However, this is not the only physiological function
of this enzyme; other functions of thrombin are:
- the activation of thrombocltes: thrombin causes platelets to aggregate and to
make available the phospholipids necessary for the clotting process (the pro-
coagulant lipid/water interface).
- the activation of the factors V and VIII.
- the activation of protein C, a vitamin K-dependent proteinase that inactivates the
factors Vu and VIII..
- partial proteolysis of the prothrombin molecule, thereby converting it into pre-
thrombin 1, a molecule that is activated much more slowly by factor Xu than the
original prothrombin moleculei this mechanism seems not to be of relevance under
in uiuo conditions.
- the activation of factor XIII: factor XIIIa stabilizes the polymeric fibrin network
by covalent linkage of the polymers.
J[1î.-,,,
' 
lr*.l*
X a '
li.'
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Present evidence suggests that the coagulation process is autocatalytic and self-limit-
ing and that thrombin plays a central role in the whole haemostasis process.
The circulation of activated coagulation factors in blood would create an extremely
dangerous situation [3]; therefore, inhibitors of the activated coagulation factors are
also present to prevent the persistence of active coagulation factors in plasma. As the
generation of active coagulation factors is explosive and is initiated by a local injury of
the vessel wall, whilst the inhibitors are present in the whole vascular system, the
active coagulation enzymes can only exist at the site of injury for a short period of
time (during which their formation proceeds much faster than their inactivation).
Together the processes described above localize coagulation to the site of injury.
Application of the methods: biochemical and medical research and clinical chemical
analysis in the field of haematology.
Enzyme properties relevant in analysis: a host of potentially active enzymes is present
in plasma among which the coagulation enzymes form a family of very similar pro-
teases. Most of them are serine proteases; the factors V" and VIII" are involved as
cofactors in reactions catalyzedby serine proteases. The blood coagulation serine pro-
teases have been shown to contain very similar active sites within the structurally
homologous regions of their molecules. They all split a peptide bond at the C-terminal
site of an Arg residue, as trypsin does. The high degree of specificity of the blood
coagulation enzymes is primarily due to the presence of an amino-terminal extension
chain, the "pro" part, which is not involved in the catalytic reaction per se.
The measurement of a specific clotting factor in plasma is not a simple straight-
forward procedure: the time course of product formation is very complicated and
depends on the concentrations of the coagulation factor to be assayed and that of
its potential activator(s) and inhibitor(s). The quantitative determinations of clotting
factor activities in plasma are therefore essentially bioassays, in which the results are
obtained by comparing the samples to be tested with a series of dilutions of a standard
plasma.
Methods of determination: the determination of coagulation enzymes can be based
upon at least two different principles: an immunological assay and a biological ac-
tivity measurement. A general disadvantage of the immunological assay techniques
is that they determine an amount of protein and not the biological activity of this
protein. Usually the one-dimensional "rocket" immunoassays do not discriminate
between the different molecular forms of the coagulation enzymes. Under some cir-
cumstances (oral anticoagulation, some types of congenital deficiencies) there may be
large discrepancies between the two types of tests.
The quantitative determination of clotting enzymes by biological activity measure-
ment is carried out in a bioassay type of determination by comparing the sample to be
tested with various concentrations of the coagulation factor, obtained by dilution of
standard plasma. A plasma deficient in the coagulation enzyme to be determined
constitutes a medium in which all coagulation factors except the one to be determined
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are present in excess. The coagulation enzyme to be determined, present in the suit-
ably diluted sample, will then be rate-limiting.
The amount of enzymatic activity generated can be measured by conventional clot-
ting techniques and by determinations carried out with synthetic substrates.
International reference methods and standards: international standardization of coag-
ulation tests is a very complicated and, so far, an incompletely solved problem. There
are at least 4 groups of variables that influence the final outcome of the coagulation
test:
1. the collection and treatment of the sample,
2. the composition of the mixture or the type of trigger used to initiate the clotting
reaction (e.g. thromboplastin, snake venoms, activated coagulation factor com-
plexes),
3. the preparation of a standard used for the construction of standard curves,
4. the instrumental details of the measurement.
The first attempt to reach international standardization of clotting tests was the intro-
duction of reference thromboplastins to which all other thromboplastins could be
compared 14-71.
In this thromboplastin calibration, the Prothrombin-Time ratios (quotient of
patient PT and mean normal PT) obtained with a series of freshly prepared plasmas
from normal subjects and from patients under stable oral anticoagulant treatment,
when tested with the thromboplastin preparation to be calibrated, are compared with
those obtained when the reference thromboplastin is used. ln 1976, the World Health
Organisation (WHO) established the human brain-type combined thromboplastin,
which contains also fibrinogen and factor V (ICTH reference material 67/40;ICTH
: International Committee on Thrombosis and Haemostasis), as the primary WHO
reference material. The term International Calibrated Ratio (ICR) was introduced
(the ratio obtained by calibration against the primary WHO reference material). In
1979,the bovine combined thromboplastin (ICTH reference material 68/434) and the
rabbit brain thromboplastin without added coagulation factors (ICTH reference mate-
rial 70/178) were accepted as secondary WHO reference materials [8,9] .
Ln1979, a report on Prothrombin Time Standardization was published by an Ex-
pert Panel of the International Committee on Thrombosis and Haemostasis (ICTH)
and the International Committee for Standardization in Haematology (ICSH) [10]. A
collaborative study from 199 laboratories was published in this report, in which 9
commercial thromboplastins, 4 thromboplastins held by the National Institute of Bio-
logical Standards & Control (NIBSC) and the British Comparative Thromboplastin
(BCT) were tested on fresh normal and coumarin plasma, and on three series of free-
ze-dried plasmas (normal and coumarin plasmas).
Implementation of the WHO recommendations in clinical practice has not been
without problems. In the first place the WHO reference material is only available in
national reference centres and is not freely available for the calibration of commercial
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thromboplastins. Furthermore, the WHO human brain preparation did not fit well
into the established British system which is also in use in other countries. Therefore,
a thromboplastin calibration study was carried out by the European Community Bu-
reau of Reference (BCR) [11]. The BCR referènce materials are available in suffi-
cient amounts for the calibration of commercial thromboplastin preparations. The
BCR preparations are a human thromboplastin, a bovine thromboplastin and a rabbit
thromboplastin. In this calibration study the traditional approach of calibration of
one thromboplastin in terms of another by a straight line through the point 1,1 was
found not to be generally valid and a rectilinear relation of the logarithms of the PT-
ratios was used [12]. It was proposed to replace the term calibration constant by the
term lnternational Sensitivity Index (IS!.
All the standardization studies described above focused upon thromboplastin stand-
ardization. International standardization based upon the use of reference plosmas has
also been proposed 173,141, but in fact standardization of both thromboplastins and
plasmas used in the calibration procedure will be necessary.
Reference plasmas are freeze-dried materials of human origin. Reference plasmas
comparable to fresh plasmas of orally anticoagulated patients can be prepared by
freeze-drying of plasma samples from coumarin-treated patients, or by selective
absorption of the vitamin K-dependent coagulation factors from normal plasma. The
first group contains decarboxy coagulation factors (cf. chapter 3.1, pp. 316-351),
whereas the second group does not. This discrepancy can possibly explain the dif-
ferent behaviour of both groups of reference plasmas towards thromboplastin prep-
arations [15] . At present, carefully prepared fresh plasma from individual patients
under stable oral anticoagulant therapy and from normal subjects still seems to be the
best standard for primary calibration of thromboplastins, although evidence is forth-
coming that lyophilized plasma prepared from patients under stable oral anticoagula-
tion can also be used for this purpose [16- 19].
The problems encountered when working with other activators, such as snake
venoms and complexes of activated coagulation factors, will not be much simpler, but
as their standardization has not been studied so widely as thromboplastin standardiza-
tion the subject will not be discussed further here.
For thrombin a WHO standard preparation is available (cf. Vol. II, chapter 2.3).
Enzyme effectors: as is common in enzymology, the catalytic efficiency of the coag-
ulation factors is influenced by the pH and ionic strength of the medium and by the
type and concentration of ions present. Ca2+ is necessary in a variety of ways for most
of the interactions of clotting factors. The medium in which the enzy'rnatic reaction is
measured has to be specified in these respects.
In the test with synthetic substrates one must always be aware that the relatively
small synthetic substrates will never be completely specific. In some instances the
specificity of an assay can be improved by adding a compound which specifically
inhibits an interfering protease (e.g. hirudin for thrombin, or aprotinin for plasmin).
During the development of a specific test, the presence of unwanted activities must
always be checked in control experiments in which all substances but the factor to be
determined are present.
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Assays
Method Design
Principle: when the biological activity of a clotting factor is determined in a conven-
tional clotting assay, a plasma congenitally deficient in the clotting factor to be deter-
mined constitutes a medium in which all coagulation factors except the one to be
determined are present in excess. The factor to be determined is added to the sample
and, through the experimental design, forms the rate-limiting step in the coagulation
cascade. The visible end-point of the process is the conversion of soluble fibrinogen
into insoluble fibrin. Quantitative analysis is based upon the measurement of the time
interval between the initiation of clotting and the appearance of a visible fibrin clot
(the clotting time). The clotting time of the sample is compared to those obtained with
a series of dilutions of a standard plasma.
Optimized conditions for measurements: since the activity of the coagulation enzymes
varies with pH and ionic strength, the presence of additional metal ions andlor other
compounds (e.g. inhibitors of unwanted enzyme activities) and temperature, rigorous
standardization of the experimental conditions is necessary. Details are given in the
individual assays described below.
The most commonly used buffers are Tris/HCl, Tris/imidazole and Michaelis
buffer. The desired ionic strength is usually obtained with NaCl. It may further be
necessary to add special substances to the reaction medium: 0.190 sodium azide
prevents microbial growth; 0.1V0 - 0.590 Carbowax 6000 (polyethyleneglycol, PEG)
prevents absorption of enzymes onto the walls of the reaction vessel. Instead of
Carbowax, 190 ovalbumin or serum albumin can be used. ln this case a check for the
absence of any activity in the albumin preparation should be made. Addition of
Carbowax 6000 or albumin is especially important when low concentrations of
(purified) enzyme are used. This problem does not arise with plasma samples, and in
general at relatively high protein concentrations.
In view of the complicated dependence of the reaction velocity upon the tempera-
ture in biological systems, the temperature must carefully be kept constant during the
determination. An assay temperature above the ambient temperature is preferable.
Coagulation assays are always carried out at 37'C.
Temperature conversion factors: because phospholipids are an essential reaction com-
ponent in coagulation systems, and because it has been shown that the temperature
dependence of this type of reaction changes abruptly at the melting temperature of the
lipid [20], it is strongly recommended to avoid the use of temperature conversion
factors.
Equipment
A thermostatted water-bath (37'C), a Kolle hook and stopwatches or a thermostatted
coagulometer. Pipettes (plastic), plastic tubes (to prepare the plasma dilutions), glass
tubes (for the assay).
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Reagents and Solutions
Purity of reagents: all chemicals used to prepare solutions must be of A. R. grade.
Preparation of solutions: all solutions in re-purified water (cf. Vol. Il, chapter
2.r .3.2).
l. Michselis buffer (barbiturate, 0.028 mol/l, acetate, 0.028 mol/l; NaCl, 0.116
mol/l; pu 7.35):
dissolve 3.86 g acetate-Na . 3H2O, 5.86 g sodium barbiturate and 6.8 g NaCl in
600ml water. After dissolution of the salts the volume is brought to 800 ml with
water and finally 200 ml HCl, 0.1 mol/\, is added. The pu is checked and adjusted
with HCl,0.1 mol/I, or NaOH, 0.1 mol/l.
2. CaCl2solution (0.033 mol/l):
dissolve 0.49 g CaCl2. z}{zO in water and adjust the volume to 100 ml.
3. Citrate solution (0.109 mol/l):
dissolve 32.1 g citrate-Na3 . 2H2O in water and adjust the volume to 1000 ml.
4. NaCl solution (saline, 0.15 mol/l):
dissolve 9 g NaCl in 1000 ml water.
5. Platelet-poor plasma:
obtain plasma from fresh blood collected in plastic tubes containing citrate (9 vol-
umes blood * 1 volume sodium citrate, 0.109 mol/l) by centrifugation (15 min at
13000 s).
6. Platelet-free plasma:
obtain platelet-free plasma by centrifugation of platelet-poor plasma (20 min at
20O00 g at 4'C).
7. Standard plasma:
obtain standard plasma by pooling equal amounts of platelet-free plasma from at
least 30 healthy individuals (15 males and 15 females, average age 30 years) and
store in small portions at -20oC or preferably at - 80'C until use.
Plasma samples to be stored should be prepared free from platelets before
storage.
8. Thromboplastin:
prepare from human brain according to a modification of the method of Owren &
Aas 121-231.
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Wash human brains under cold running water. After the removal of membranes
and blood vessels, repeat washing with NaCl solution (4), cut the brains into small
pieces and add 1.5litre NaCl solution (4), pre-warmed to 37'C. Homogenize the
mixture and keep it at 37 " C for 720 min. Then add 0.5 litre buffered NaCl solu-
tion (9 parts NaCl solution (4) + | part Michoelrs buffer (1)) to the suspension.
Centrifuge the mixture for 30 min at 1250 g and carefully pipette off the super-
natant. The supernatant can usually be diluted without significant loss of activity.
For this purpose, determine the thromboplastin times of a series of diluted solu-
tions of the supernatant (made in the buffered NaCl solution described above)
acting on standard plasma. In practice, the diluted solution that gives a thrombo-
plastin time of 13 seconds is chosen. After dilution store the product in small por-
tions at -20"C preferably at -80"C until use. Prior to use pre-warm the
thromboplastin solution at 37 "C for at least 20 min and not more than 120 min.
9. Phospholipid (cephalin) suspension (ca. 28 e/D:
prepare according to a slight modification of the method of Milstone 122-241.
Wash human brains under cold, running water. After the removal of membranes
and blood vessels, repeat washing with NaCl solution (4). Remove the cortex and
homogenize the cortex in 300 ml acetone. Centrifuge the suspension for 15 min at
1250 g and remove the supernatant. Repeat he washing about 6 times, using fresh
acetone each time. Extract the residue with 1.8 litre ether during about 12h at
room temperature. Remove the ether fraction and evaporate the ether on a water-
bath at 35"C. Wash the residue twice with acetone (washing during 15 min with
900 ml acetone followed by centrifugation for 15 min at 1250 g). Dissolve the
residue in 200 ml ether. Evaporate the ether as described above and finally
evaporate the residue under vacuum for 75 min. Suspend the residue (about 10g)
in 200 ml Michoelis buffer (1) with the aid of a blender. Centrifuge the suspension
for 20 min at 350 g and thereafter for 10 min at 750 g. Discard the sediment. Store
the supernatant, containing about 2.8 g cephalin per 100 ml, in small portions at
-20"C or - 80oC. Prior to use dilute the phospholipid suspension with Michae-
/is buffer (1); tne final dilution depends on the specific test to be carried out.
10. Kaolin/phospholipid suspension (kaolin, 2l g/l; phospholipid, 0.5 g/l):
suspend 4.17 g koalin in 100 ml NaCl solution (4). Prepare the kaolin/phospho-
lipid suspension immediately before use accordingto Horowitz et al. [25]. After
thawing dilute the phospholipid suspension with Michaells buffer (1) to a final
concentration of 1 mglml. Mix equal volumes of phospholipid suspension (9) and
kaolin suspension.
11. Clotting factor-deficient plasma:
plasma deficient in the factors II, V, VII, VIII, IX, X and XI respectively can be
obtained commercially.
Factor-deficient reagents can also be prepared from plasmas from patients with a
congenital deficiency or can be prepared artificially as indicated below.
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a) Factor Il-deficient reagent: according to a modification of the method describ-
edby Koller et al.122,23,261.
b) Factor V-deficient reagent: according to Borchgrettink et al.1271.
c) Factor Vll-deficient reagent: according to Hemker et ol.1281.
d) Factor X-deficient reagent: according to Hemker et al.1281.
e) Factor Vlll-deficient reagent: according to Chantorangkul 1291.
f) Factor IX-deficient reagent: from commercial sources.
g) Factor Xl-deficient reagent: according to Horowitz et al.125).
The amount of factor y in a factor y-deficient reagent must be lower than 190; this can
be checked by the method described by Hemker et sl.1281.
Stabil ity of solutions: store all buffer and salt solutions (1)-(4) at 0-4'C. Buffer
and salt solutions will be stable as long as no microbial contamination occurs. Throm-
boplastin solutions (8), platelet-free plasma (6), factor-deficient reagents (11,12) and
phospholipid suspension (9) have to be stored at -20'C or preferably at - 80oC and
will be stable under these conditions for at least I year. Once thawed, the solutions
must be kept on ice and used within a few hours.
Procedure
Collection and treatment of specimen: collect blood obtained by venepuncture with-
out stasis in plastic tubes containing citrate (9 volumes blood + 1 volume sodium
citrate solution, 0.109 mol/l). Discard the first few ml of blood if possible. Some types
of vacuum tubes may cause an increased activation of plasma factors.
Prepare platelet-poor plasma by centrifugation (15 min at 13000 g). Use only
plastic materials during the blood sampling and plasma preparation procedures. Store
plasma samples at - 20" C or - 80'C prior to testing; the samples must be prepared
free from platelets prior to storage (20 min centrifugation at 20000 g ar 4"C).
Stability of the enzyme in the sample: if frozen at - 20o C or - 80 o C the enzymes in
plasma will be stable for at least I year; once thawed the solutions must be kept on ice
and used within a few hours.
The stability in solution of purified factors is at least the same as that described
above for plasma; in diluted solutions it may be necessary to prevent adsorption of the
enzymes to the vessel wall by the addition of 0.190-0.590 Carbowax 6000 or 190
ovalbumin or serum albumin.
Assay conditions: clotting assays are carried out in glass tubes in a thermostatted
water-bath or in a thermostatted coagulometer at 37"C; dilutions of sample and
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standard plasma are made in plastic tubes. Pre-warm thromboplastin solution (8) (for
at least 20 and not more than 720 min) and CaCl2 solution (2) to 37'C.
Prior to measurement the sample to be determined is diluted 1:10 or 1:20 in
Michselis buffer (1). All determinations are carried out in duplicate. Assay volume
0.4mI; volume fraction of sample 0.25.
Measurement: factors II, V, VII, and X
+ final concentration 8.25 mmol/l
The clotting time measured with the unknown sample must lie within the range
obtained with the diluted solutions of the standard plasma. The drawbacks of this
method are numerous [28].
Standard curve: the following dilutions of standard plasma in Michaelis buffer (1) are
used for  the construct ion of  the reference curve:  1090,  5V0,2.5V0, l .67Vo, l .25Vo,
7Vo.  0.5 Vo.
The clotting times obtained with the dilutions of the standard plasma are tradition-
ally plotted against the factor y concentration (in 9o of standard plasma; y : II, V,
VII or X) on double logarithmic paper and this graph is used to read the factor con-
centration in an unknown sample, the coagulation time of which is known.
Calculation: the amount of factor Il, V, VII or X, respectively, in the inknown sample
has to be determined by comparison of the clotting time obtained with the diluted
sample to the clotting times obtained with a series of diluted solutions of standard
plasma.
For the factors of the extrinsic system (II, V, VII, X) the relationship found by
Hemker et sl. can be used:
I
t p :  t ^ i n *  P z t ^ i n X  t p X
P r t  P s
Pipette successively into a glass tube:
congenital or artificial factor II, V, VII or X-deficient
reagent
diluted sample or diluted standard plasma
thromboplastin solution
(11 a/b/c/d)
(7)
(8)
0 . 1 m I
0 . 1 m I
0 . 1 m 1
incubate 30 s
CaCl2 solution* (2) 0 . 1 m I
record the clotting time (time interval between CaCl2 addition and
the appearance of the fibrin clot).
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in which
tp coagulation time, min,
lmin minimum coagulation time at infinite concentration of the rate limiting factor,
min.
pzt^in clotting factor concentration that will cause a to: 2 X /61ni 9o of standard
plasma,
p, clotting factor concentration in the reagenti 9o of standard plasma,
ps clotting factor concentration in the samplei 9o of standard plasma.
In a given assay system tmin, pzt^inand pl are constants which may be deduced from the
data obtained with known sample concentrations, by calculation or by a computer
program [28]. The constants t^in, pzt^inand p, must be determined each time a new
batch of thromboplastin or reagent solution is used. The level of clotting factor in the
unknown sample can be read from the double logarithmic plot or from a computer-
constructed reference table [28].
Measurement: factors VIII. IX and XI
The clotting time measured with the diluted unknown sample must lie within the range
obtained with the dilutions of the standard plasma.
Standard curve: the following dilutions of standard plasma (in buffer 1) are used for
the construction of the standard curve: 2.590, l.67Vo, 1.25V0, 1.090, 0.590. The
Pipette successively into a glass tube: concentration in
mixture
assay
congenital or artificial
factor VIII. IX or
XI-deficient
reagent (11 e/f/g)
diluted sample or
diluted standard plasma (7)
kaolin/phospholipid
suspension (10)
0 . 1 m I
0 . 1 m l
0 . 1 m I kaolin
phospholipid
CaCl2
0.12  g / l
5.21 s/ l
8.25 mmol/ l
incubate 20 min at 37 o C
CaCl2 solution (2) 0 . 1 m l
record the clotting time
(time interval between the addition of CaCl2 and
the appearance of the fibrin clot).
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clotting times obtained with the dilutions of the standard plasma are plotted against
the factor y concentration (in 9o of standard plasma; y : VIII, IX or XI) on double
logarithmic paper, as here the relationship t, : f(p) is unknown.
Calculation: the amount of factor VIII, IX or XI, respectively, in the unknown
sample has to be determined by comparing the clotting time obtained with the sample
to the clotting times obtained with a series of diluted solutions of standard plasma.
The amount of the corresponding factor in the unknown sample can be read from the
double logarithmic plot and expressed in 9o of standard plasma.
Validation of Methods
Precision, accuracy, detection limit and sensitivity: in the concentration range of
10- 10090 of standard plasma, one-stage estimations of the extrinsic coagulation
factors (II, V, VII, X) show a standard deviation in our hands of 7-1090. The
standard deviations of one-stage estimations of the intrinsic system factors (VIII, IX,
XI) are from 10- 1690.
The detection limit is about lVo of the activity present in standard plasma. The
lower detection limit is dependent upon the residual activity of the respective coagula-
tion factor in the reagent used.
A very precise method to calculate concentrations from 0.05-2Vo of standard
plasma is offered by the use of the computer program available from the authors.
Sources of error: in a clotting assay, the amount of a specific clotting factor in the
sample has to be determined from its influence upon the overall coagulation process.
Therefore, the activity measured is determined not only by the total amount of the
clotting factor but also by its actual molecular structure (slight differences in the
molecular form of a clotting factor may have very important consequences for its
biological activity), and by the presence of potential activators(s) and inhibitor(s) in
the test system. It is evident that in bioassays of this type a rigorous standardization of
the experimental conditions is necessary.
Specificity: the experimental design of the clotting assay is such that the clotting factor
to be determined forms the rate-limiting step in the coagulation cascade. However,
when a specific test is carried out in a complicated biological system, the presence of
unwanted activities must always be checked in control experiments in which all sub-
stances but the factor to be determined are present.
Reference ranges: given as approximate concentrations in plasma in nmol/l corres-
ponding to the 10090 values of the respective standard plasma:
Factor
Ref. range
I I
1500
VII
1 0
VII I
0.2
I X X X I
70 180 30
V
30
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3,2.2 Blood Coagulation Factors II, V, VII, VilI, IX, X
ANd XI:
Determination with Synthetic Substrates
Maria C. E. van Dam-Mieras, Annemarie D. Muller,
Gerbrand van Dieiien and H. Coenraad Hemker
General
For information on the coagulation cascade, enzyme properties, application of meth-
ods, methods of determination and standardization cf. chapter 3-2.1, pp. 352-356.
Assays
Method Design
Principle: with the use of synthetic substrates it is no longer necessary to measure a
coagulation enzyme through its influence upon the complete coagulation cascadei
synthetic substrates make possible the measurement of isolated steps of the coagula-
tion process. Synthetic substrates contain a peptide part, designed to be relatively
366 3 Blood Coagulation Factors
specific towards a given coagulation factor, and an additional group which produces a
physically measurable ffect when it is split off from the substrate (there are, e.g.,
chromogenic, fluorigenic, luminogenic and electrogenic leaving groups [1]).
The principle of activity determinations with synthetic substrates is depicted in
Fig. 1. Because the first step in the reaction sequence is rate-limiting, the liberation of
the leaving group is a measure of the velocity of substrate hydrolysis.
Peptide-NH{tZlhNO, + enzvme
It*
A
Pept id e-Ntl {tZhlvar,' e nzyme
( P r )
I
Pept ide-enzyme + Nur@No,
1"."I
Pept ide  +  enzyme
( P z )
ï:;l lt,".tPte 
of the clotting factor activity determination with a chromogenic substrate. For details,
A problem encountered when setting up an assay of coagulation parameters with a
synthetic substrate is that clotting factors occur in blood as inactive zymogens, which
must be activated before the activity can be determined in a synthetic substrate assay.
Therefore, the procedure must be as follows:
Clo t t i ng  f ac to r
I  
<-  act i .vator
Ac t i ve  c l o t t i ng  f ac to r
Syn the t i c  subs t ra te  ù  '  pep t i de  pa r t  +  l eav ing  g roup .
Test procedures with synthetic substrates are relatively simple and can be automated.
However, the small synthetic substrates will never be completely specific and differen-
ces between the enzymatic activities towards natural and synthetic substrates will
occur. Therefore, the determination of coagulation enzymes in biological material
with synthetic substrates can only be carried out properly in a "bioassay type" deter-
mination. This means that the change in the physical parameter produced by the
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enzyme to be determined must be compared with the changes produced in that para-
meter by a series of dilutions of standard plasma. Only in model systems with purified
coagulation factors can real "chemical determinations" be carried out with synthetic
substrates.
Examples of chromogenic substrates*:
s 2222
s 2337
s 2238
s 2160
Chromozym@ TH
Bz- lle-Glu-COR)-Cly-Arg-4-NA
Bz- Ile-Glu-(y-Piperidyl)-Cly-Arg-4-NA
H- D- Phe-Pipq-Arg-4-NA
Bz-Phe-Val-Arg-4-NA
Tos or CBz-Gly-Pro-Arg-4-NA
+ The substrates of the "S" series are madeby Kabi Vitrum AB, Stockholm, Sweden and the "Chromo-
zyme" series by Pentopharm, Basel, Switzerland.
When synthetic substrates are used for the detection of enzymatic activity they should
preferably be added at a concentration at least two times K*. Also, the change in the
physical parameter to be measured should be large enough to give reliable data. The
implications of the latter requirement for the substrate concentration to be used de-
pend on the type of leaving group. These conditions will be specified in the individual
assays to be described.
Equipment
A thermostatted water-bath (for pre-warming the bulk medium), a spectrophotometer
or spectral-line photometer capable of exact measurement at a wavelength in the range
of 380-410 nm with a thermostatted cuvette holder, a fluorimeter with a thermo-
statted cuvette holder, a recorder or stopwatch, pipettes, cuvettes.
3.2.2.1 Determination of Factor IIu (Thrombin) and Other Assays
Based on Factor II" Determination
Thrombin can be measured with the chromogenic substrates S 2238, S 2160 and
Chromozym@ TH*. These substrates are not only split by c-thrombin, but also by
p-thrombin, y-thrombin, meizothrombin and coagulase-thrombin.
The specific activities of the various forms of thrombin towards different chromo-
genic substrates may vary 12, 3, 4l . Much less variation is encountered, however, with
synthetic substrates than with natural substrates. Therefore, there is not necessarily a
fixed relation between biological and amidolytic activity in different thrombin
preparations.
* Registered trademark of Pentapharm AG, Basel, Switzerland, supplied by Boehrinoer Mannheim
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Factor Iluestimation is the basis of various assays for/actor II, antithrombin III
(heparin cofactor), heparin and antiheparins such as plotelet factor 4. In addition, the
factors constituting the prothrombinose complex can be measured by assessing the
velocity of factor II activation; this leads to factor V and platelet factor 3 determina-
tions.
Equipment
Spectrophotometer capable of exact measurement at 405 nm; thermostatted cuvette
holder.
Reagents and Solutions
Purity of reagents: all chemicals used must be of analytical grade.
Preparation of solutions: all solutions in re-purified water (cf. Vol. II, chapter
2 .1 .3 .2 ) .
1. Tris buffer (Tris, 50 mmol/l; NaCl, 0.1 mol/l; pu 7.8):
dissolve 6.05 g tris(hydroxymethyl)aminomethane and 5.84 g NaCl in 900 ml
water. Bring the pu to 7.8 with 3790 HCI and afterwards bring the volume to
1000 ml with water. Measure the pH and adjust it to 7.8 with HCl, 0.1 mol/l or
NaOH,0.1 mol / I .
2. Tris buffer (Tris, 50 mmol/l; NaCl, 0.1 mol/l; human serum albumin, 0.5 mglml;
pH 7.8) :
supplement Tris buffer (1) with 0.5 g human serum albumin per 1000 ml.
3. Tris buffer (Tris, 50 mmol/l; NaCl, 0.1 mol/l; human serum albumin, 0.5 mg/ml;
EDTA, 20 mmol/l; pu 7.8):
supplement Tris buffer (1) with 0.5 g human serum albumin and 7.44gEDTA-
Na2 ' 2 H2O (Titriplex III, Merck, Darmstadt) per 1000 ml.
4. CaCl2 solution (0.1 mol/l):
dissolve 1.47 g CaCl2 . 2 FJ1O in water and adjust the volume to 100 ml.
5. Citrate solution (0.109 mol/l):
dissolve 32.7 g citrate-Na3 . 2 H2O in water and adjust the volume to 1000 ml.
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6. Platelet-poor plasma:
cf. solution (5), p.358.
7. Platelet-free plasma:
cf. solution (6), p.358.
8. Standard plasma:
cf. solution (7), p.358.
9. Russell's viper venom (RVV*) solution (0.1 mglml):
dissolve 1 mg RVV in water and adjust the volume to 10 ml.
10. Soybean trypsin inhibitor (SBTI) solution (inhibitor, 4 mg/ml; Tris, 50 mmol/l;
NaCl, 0.1 mol/l; pH 7.8):
dissolve 40 mg soybean trypsin inhibitor in Tris buffer (1) and adjust the volume
to 10 ml.
11. Phospholipid suspension (0.75 mg/ml;25V0 of which is brain phosphatidylserine
(PS) and 75Vo egg phosphatidylcholine (PC); Tris, 50 mmol/l; NaCl, 0'1 mol/l;
pH 7.8):
purify brain PS from brain extract (Folch III extract, Sigma) according to Com'
furius & Zwaol [5]. Dissolve 500 mg brain extract in 10 ml chloroform and apply
to a CM-cellulose column (CM-52, Whatman) equilibrated with chloroform. Use
1 ml CM-cellulose per 5 mg total lipid. Subsequently elute the column with 3
(column) volumes chloroform, 3 volumes chloroform/methanol 9:1, and 20
volumes chloroform/methanol 8: 2. Elute the PS from the column with 5 volumes
chloroform/methanol 1 : 1. Discard the first 0.5 volume of the 1 : 1 eluate. Dry the
remaining 4.5 volumes by rotary evaporation and dissolve the PS in chloro-
form/methanol 1: 1 in a concentration of 10 mglml.
Obtain a 10 mg/ml solution of egg PC in chloroform/methanol I : 1 by diluting
a solution containing 100 mg egg PC per 100 ml chloroform/methanol (1:1)
(Sigma) 1:10 with chloroform,/methanol 1:1.
Prepare the phospholipid suspension by mixing 0.37 ml PS solution (10 mglml
in chloroform/methanol 1:1) with 1.13 ml PC solution (10 mglml in chloro-
form/methanol 1 : 1). Remove the organic solvent by a stream of nitrogen. To the
dry lipids add 2 ml Tris buffer (1) and suspend the lipids by agitating on a vortex
mixer for 5 minutes. Prepare single bilayer (unilamellar) vesicles by sonicating the
* RVV Rrsse//'s viper venom
SBTI soybean trypsin inhibitor
PS phosphatidylserine
PC phosphatidylcholine
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lipid suspension for 10 min at 0oC, using a MSEMark II 150 watt ultrasonic des-
integrator. Place the end of the tip of the sonication probe in the middle of the
lipid suspension. Energy output is at 8 micron peak-to-peak amplitude. Dilute the
stock solution of 7.5 mglml lO-fold in Tris buffer (1) and store the solutions
(0.75 mglml) at -70'C. After thawing, re-sonicate the phospholipid suspension
as described above.
12. S 2238 solution (2.35 mmol/l):
dissolve the content of one vial S 2238 (25 mg) in 17 ml water to obtain a stock
solution of 2.35 mmol/I.
13. Factor II solution (10 pmol/l):
in Tris buffer (2); cf. Appendix, p.390, or obtain commercially.
14. Factor Xu solution (150 nmol/l and 0.05 nmol,/I, respectively):
in Tris buffer (4; cf . Appendix, p.392, or obtain commercially.
Stabil ity of solutions: store all buffer and salt solutions (1)-(5) at 0-4'C;they are
stable as long as no microbial contamination occurs.
Plasma (6)-(8), factor II (13) and factor X (14) solutions and phospholipid
suspension (11) have to be stored at -20'C or - 80'C and are stable under these cir-
cumstances for at least one year. Once thawed, the plasma, factor II and factor X
solutions must be kept on ice and used within a few hours. The phospholipid suspen-
sion must be re-sonicated after thawing (2 min at 0oC, 8 micron peak-to-peak ampli-
tude) and is stable for 2 weeks at 0oc. SBTI and RVV solutions (10), (9) are stable at
OoC for several days.
Chromogenic substrates are best dissolved in sterile distilled water not above a
temperature of 50"c. This wil l give a pH of 4-6. Maximal stabil ity is obtained
around PH 4i lower ptt values are to be avoided as they can cause acid hydrolysis of
the substrate. Synthetic substrate solutions are stable for at least 1 month at 5oC or
below. No destruction by light has been observed. Micro-organisms may break down
the substrate rather quickly: nitroaniline formation is the first sign of breakdown. The
addition of a drop of thymol will protect against microbial growth.
Procedure
Collection and treatment of sample: cf. p.360.
stability of the enzyme in the sample: to prevent adsorption of the enzyme to the
vessel wall, all dilutions of enzymes and plasma are made in buffer containing
0.5 mglml human serum albumin or 0.1-0.590 polyethylene glycol (Carbowax
6000).
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Assay conditions: wavelength 405 nm; plastic cuvettes, 10 mm light pathi 37 oC; assay
volume 1000 pl. Pre-warm buffer to 37"C.
Measurement: factor II" (thrombin) [11
lf LA/L1 is greater than 1 min r, the samples must be diluted appropriately with
buffer (3).
If interference by factor Xu in a thrombin-containing sample is suspected, add 10 pl
of soybean trypsin inhibitor solution (10); ttre final concentration will be 40 pg/ml.
Standard curve: construct a standard curve by plotting LA/ Lt in min 
- I obtained with
dilutions of the standard plasma against their concentrations, expressed as 9o of
standard plasma.
Calculation: the reaction velocity is best compared to that obtained with dilutions of a
thrombin standard. For determinations in plasma, standard plasma can serve this
purpose; for measurements in systems containing purified factor IIu an active-site
titrated factor IIu preparation is the best standard'
Measurement: factor II (prothrombin) [1,6]
Factor II (prothrombin) in plasma can be determined after quantitative conversion
into factor IIu (thrombin) by a suitable activator. A satisfactory arrangement for
measuring proihrombin is the following: factor Xu, phospholipid and Ca2+ are added
to plasma to convert prothrombin into thrombin; the amount of thrombin formed is
measured with a chromogenic substrate. Under the experimental conditions described
below, the quantitative conversion of prothrombin into thrombin is achieved within
120 s, provided that the plasma sample contains at least 3090 of factor V. Soybean
trypsin inhibitor must be added thereafter to inhibit factor Xu, which also hydrolyzes
the chromogenic substrate.
Pipette into a plastic semi-micro cuvette: concentratlon ln assay
mixture
Tris buffer (3)
52238 solution (É2)
sample, factor IIu (thrombin)
solution
800 pl
100 pl
100 pl
Tris 40 mmol/l
NaCl 8Ommol/l
albumin 0.4 mglml
EDTA 16mmol/l
52238 0.24mmol/l
volume fraction 0.1
mix, monitor the absorbance increase due to
4nitroaniline production continuously or at
fixed time intervals (every 15 s) during 3 min.
372 3 Blood Coagulation Factors
Pipette into a plastic semi-micro cuvette: concentration in assay
mixture
sample, undiluted plasma or
another factor II (thrombin)-
containing solution
phospholipidsuspension (11)
factor Xu solution
(150 nmol/l) (14)
CaCl2 solution (4)
Tris buffer (2)
l - 4 p l
10 pl
10  p l
40 pl
330 pl
volume fraction
0.001 - 0.004
PS 1.88 mgl l
PC 5.62m9/l
F X u
CaCl2
SBTI
Tris
NaCl
albumin
EDTA
s2238
1.5 nmol/ l
4 mmol/l
0.04 mglml
43 mmol/l
0.086 mol/l
0.42 g/l
10 mmol/l
0.24mmol/l
incubate 720 s at 37'C
SBTI solution (10)
Tris buffer (3)
s2238 (12)
10 pl
500 pl
100pl
mix, monitor the absorbance increase due to
4-nitroaniline production continuously or at
fixed time intervals (every 15 s) during 3 min.
lf the LA/A^/ is greater than 1 min-r the samples must be appropriately diluted with
buffer (2).
Standard curve: construct a standard curve by plotting LA/Lt in min - 1 obtained with
dilutions of the standard plasma against their concentrations, expressed as go of
standard plasma.
Calculation: the results are expressed as percentage factor II (prothrombin) relative to
a standard plasma. Therefore, the reaction velocity obtained with the sample must be
compared to velocities obtained with a series of dilutions of standard plasma.
Measurement: factor V [1]
Factor V in plasma can be determined after quantitative conversion into factor V" by
Russell's viper venom (RVV).Factor Vuis an essential cofactor in the activation of
prothrombin by the prothrombinase complex (thrombin activating complex consisting
of factor Xu, factor vu, phospholipids and ca'*). By a suitable experimental design,
factor Vu can become the rate-determining reaction constituent. The principle of the
factor V determination presented below is the following: factor V in plasma is rapidly
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activated into factor Vu by RVV. Factor X", phospholipid and Ca2* are added and
the mixture is incubated for 5 minutes to allow assembly of factor Xu and factor Vu at
the lipid surface. Thrombin formation is started by addition of prothrombin. The
initial rate of thrombin formation is determined from the amount of thrombin present
after 2 minutes. Under the experimental conditions described here, the rate of
thrombin formation is proportional to the amount of factor Vu present in the assay
mixture.
* 0.05 x 10-a calculated on undiluted plasma.
+* 10 pl solution (10) diluted with Tris buffer (3) to 400 pl.
Pipette into a plastic semi-micro cuvette: concentration in assay
mlxture
sample (normal plasma should
be diluted about I : 10000 in
this assay)
Russell's viper venom
solution (9)
50 pl
5 p l
volume fraction
RVV
0.05 +
0.5 mgll
PS
PC
FX"
CaCl2
factor II
0.93mg/l
2.80mg/l
5 pmol/l
4.98 mmol/l
0.5 pmol/l
0.04 g/1
42mmol/l
84 mmol/l
0.42 s/l
78 mmol/l
SBTI
Tris
NaCl
albumin
EDTA
s2238 0.23 mmol/l
incubate 1 min at room temperature
Tris buffer Q\
phospholipidsuspension (11)
factor X" solution (14)
CaCI2 solution (4)
245 pl
5 p l
100 pl
50 pl
incubate 5 min at 37"C
prothrombin solution (13) 50 pl
wait exactly 2 min
soybean trypsin inhibitor
solution (10) ** 400 pl
mlx
52238 solution (12) 100 ul
monitor the absorbance increase due to the
4-nitroaniline production continuously or at
fixed time intervals (every 15 s) during 3 min.
374 3 Blood Coagulation Factors
If LA/ Lt is greater than 1 min - 1 the samples must be appropriately diluted in buffer
(2).
Standard curve: construct a standard curve by plotting LA/Lt in min I obtained with
dilutions of the standard plasma against their concentrations, expressed in 9o of
standard plasma.
Calculation: the results are expressed as percentage factor V relative to a standard
plasma. Therefore, the reaction velocity obtained with the sample must be compared
to velocities obtained with a series of dilutions of standard olasma.
Validation of Methods
Precision, accuracy, detection limit and sensitivity: in a concentration range of
10- 10090 of standard plasma, chromogenic substrate assays of the factors II and V
show a standard deviation of 3-4Vo in our hands.
Spectrophotometric determinations are most accurate in the range between A :
0.080 and ,4 : 0.800; when the chemical system allows, it is best to adapt it so that
this range is covered by the assay. Because of optical limitations, some spectrophoto-
meters may give non-linear responses at A > 1.0. The absorbance of 4-nitroaniline is
linear with concentration from about 1-200 pmol/l (roughly ftom A: 0.010 to
A : 2.0\ in water and in Tris buffer. 0.05 mol/I.
The lowest velocity that can be measured with accuracy in a typical spectrophoto-
merer  is  about  LA/L/  :  0 .010 min-r .
The detection limit of chromogenic substrate assays in biological systems is not only
determined by the optical system but also by the presence of other (unwanted) activi-
ties in the sample.
The concentration of 52238 in the cuvette is 0.235 mmol/I. This is about 8 times the
K- value of thrombin for S 2238. Thus, extensive substrate conversion by thrombin
will not lead to non-linearity of 4-nitroaniline production due to substrate depletion.
Chromozym@ TH and 52238 have similar kinetic parameters for thrombin, and both
are suitable for thrombin measurements. However, Chromozym@ TH is more easily
converted by bovine factor Xu than S 2238. When Chromozym@ TH and bovine
factor Xu are used, addition of soybean trypsin inhibitor is recommended.
Sources of error: as the chromogenic substrate assay remains a bioassay in principle,
rigorous standardization of the reaction conditions is necessary. Furthermore, chro-
mogenic substrates are never completely specific and other enzymes may be present in
biological samples which are also active towards the chromogenic substrate used, and
which will therefore interfere with the determination.
In all tests in which thrombin is formed, fibrin clots interfering with the measure-
ment can be formed. This source of error can be eliminated by the use of defibrinated
plasma or by working with diluted plasma samples. Opalescence in the assay solutions
(e.g. caused by heparin, thromboplastin, protamine sulphate, lipaemic plasma, etc.)
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prevents precise optical determinations. This source of error can also be ameliorated
by the use of diluted plasma samples.
The choice of a factor II activator in the factor II assay is crucial. Non-physiologi-
cal activators such as staphylocoagulase and snake venoms will not discriminate
between normal prothrombin and decarboxyprothrombin (i.e. the abnormal pro-
thrombin present during oral anticoagulant therapy, also called PIVKA). Hence'
these activators are unsuitable for the estimation of the level of functional prothrom-
bin in vitamin K deficiency (and also in various forms of liver disease) or during oral
anticoagulation. The only known activator that differentiates between the two species
is the physiological prothrombinase complex consisting of factor Xu, factor Vu and a
suitable phospholipid 16l. The factor II test described above is specific for normal pro-
thrombin and is independent of factor V and factor X levels in plasma. It can be made
independent of heparin by the addition of polybrene'
It has been observed that the generation of factor II" by factor Xu (plus phospho-
lipid and factor Vu) is markedly inhibited in the presence of chromogenic substrates
for thrombin [7]. This hampers the direct monitoring of factor IIu generation by
following chromogenic substrate hydrolysis. Moreover, production of 4-nitroaniline
will not be linear in an assay system containing both factor Xu and prothrombin.
In assays for factor II, therefore, the activation by factor Xuhas to take place in the
absence of the chromogenic substrate, i.e. a pre-incubation is always necessary. For
the same reasons the presence of chromogenic substrate in the activation mixture of
the factor V assay is better avoided.
The determination of factor V depends on the activation of factor II by a pro-
thrombinase complex in which the factor V concentration is rate-limiting. In this
respect it must be stressed that the V and K^values of the factor II activation reaction
are dependent upon the amount and composition of the lipid present [8], which makes
standardization of crucial importance.
Reference ranges: factor IIu (thrombin) is absent from normal plasma. In the test
system describèd above a thrombin concentration in the cuvette of 10-e mol/l (:
1 pmol/ml = 0.1 NIH unit/ml) will cause a change in absorbance at 405 nm of 0.095
absorbance units/min.
The concentration of factor II in normal plasma is 1.5 x 10 6 mol/l. 1 pl of normal
plasma will cause an increase in absorbance of about LA/LI : 0.150 min-'in the
test system described above.
The concentration of factor V in normal plasma is 3 x 10-o mol/I. 1 pl of normal
plasma diluted 1 : 10000 with buffer will cause an increase in absorbance of about
LA/Lt = 0.020 min-1 in the assay system described above.
3.2.2.2 Determination of Factor Xo and Other Assays Based on
Factor X" Determination
Factor X" can be readily measured with the chromogenic substrates S 2222 and
S 2337. Bovine plasma contains two distinct forms of factor X, called factor X1 and
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factor X2 [9]; only one form is present in human plasma. From each form of factor X
two forms of factor X" can be produced, called factor Xu u and factor X" p [10] .
There are no indications that the kinetic properties of the a and p forms towards
synthetic substrates âre different [111. The abnormal factor Xu that is formed by
activation of decarboxy-factor X with Russell's viper venom (RVV) has the same
kinetic properties towards S 2222 as the normal factor Xu. However, decarboxy-
factor X is activated at a much slower rate by RVV than normal factor X. Therefore,
an RVV test for factor X can be used to monitor oral anticoagulant therapy.
The estimation of factor Xu can serve as the basis for the assessment of factor X,
sntithrombin III (and thus heparin and platelet factor 4) and the constituents of the
factor X activating complexes, i.e. factor VII, factor VIII, factor IX, plotetet factor 3
and tissue thromboplastin.
Equipment
Spectrophotometer capable of exact measurement
holder.
Reagents and Solutions
at 405 nm; thermostatted cuvette
Purity of reagents: all chemicals used must be of analytical grade.
Preparation of solutions: all solutions in re-purified water (cf. vol. II, chapter
2 . 1 . 3 . D .
Solut ions (1)-(8):  cf .  solut ions (1)-(8),  pp.368,369.
9. Michaelis buffer:
cf .  solut ion (1),  p.358.
10. NaCl solution:
cf. solution (4), p. 358.
11. Thromboplastin:
cf .  solut ion (8),  p.358.
12. Russell's viper venom (RVU solution (0.12 mglml):
dissolve 1.2 mg RVV in water and adjust the volume to 10 ml.
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13. Phospholipid suspension (0.75 mglml; 4090 phosphatidylserine, PS, 6090 egg
phosphatidylcholine, PC; Tris, 50 mmol/l; NaCl, 0.1 mol/l; pH 7.8):
purify PS from brain extract as described for suspension (11)' p' 369.
Obtain a 10 mglml solution of egg PC in chloroform/methanol 1 : 1 by diluting
a 100 mglml solution of egg PC in chloroform/methanol 1 : 1 (Sigmo) 1 : l0 with
chloroform/methanol 1 : 1.
Prepare the phospholipid suspension by mixing 0.6 ml PS solution (10 mglml in
chloroform/methanol 1:1) with 0.9 ml PC solution (10 mglml in chloroform/
methanol 1:1). Continue the procedure as described under suspension (11)'
p.  369.
14. S 2337 solution (1.92 mmol/l):
dissolve the content of I vial 52337 (24mù in 15 ml water and dilute further with
water until a 1 : 100 dilution of the stock solution gives an absorbance at 316 nm of
A : 0.250.
15. Factor IIu solution (90 nmol/l):
in Tris buffer (2); cf. Appendix, p.390, or obtain commercially.
16. Factor IXu solution (2.5 pmol/l):
in Tris buffer (2); cf. Appendix, p'392, or obtain commercially.
17. Factor Xu solution (1 nmol/l):
in Tris buffer (2); ct. Appendix, p.392.
18. Factor X solutions (1 pmol/l (a) and 10 pmol/l (b), respectively):
in Tris buffer (2); ct. Appendix, p.390'
19. Factor XI" solution (0.225 mg/ml):
in Tris buffer (2); cf. Appendix, p. 391.
Stability of solutions: as given on p. 370; this includes factor IX, factor XI and throm-
boplastin solutions as well.
For the stability of chromogenic substrates cf. p. 370.
Procedure
Collection and treatment of sample: cf' p. 360.
Stability of the enzyme in the sample: cf. p. 360 and p' 370.
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Assay conditions: wavelength 405 nm; plastic cuvettes, light-path 10 mm; 37 o C; assay
volume 1000 pl. Pre-warm buffer to 37'C.
Measurement: factor Xu [1]
Pipette into a plastic semi-micro cuvette: concentration in assay
mixture
Tris buffer (3)
52337 solution (14)
sample (containing
factor X")
800 pl
100 pl
100 pl
Tris 40 mmol/l
NaCl 8Ommol/l
albumin 0.4 g/l
EDTA 16 mmol/l
52337 0.19 mmol/l
volume fraction 0.1
mix, monitor the absorbance increase due to
4-nitroaniline production continuously or at
fixed time intervals (every 15 s) during 3 min.
lf the LA/L^/ is greater than 0.4 min-', the samples must be appropriately diluted
with buffer (3).
If factor Xu has to be measured in intact plasma, the plasma (blood) must be mixed
with an excess of antithrombin IIl-directed immunoglobulins immediately upon vene-
puncture. This test has been described by Vinazzer & Heimburger $21who used 6 pl
blood in the assay described above.
Standard curve: construct a standard curve by plotting LA/ Lt in min - I obtained with
dilutions of the standard plasma against their concentrations, expressed in Vo of
standard plasma.
Calculation: the reaction velocity is best compared to velocities obtained with dilu-
tions of a factor X" standard. For determinations in plasma, standard plasma can
serve this purposei for measurements in systems containing purified factor X" an
active-site titrated factor X" preparation is the best standard.
Measurement: factor X [1,13]
Measuring factor X means measuring factor Xu after suitable activation. For the
determination of factor X in plasma, the factor X activating protease from Rassel/'s
viper venom (RVV-X) seems to be the activator of choice. No lipid is necessary in this
reaction; in fact, lipid inhibits activation because RVV-X acts only on free, non-
adsorbed factor X [14] . In the absence of lipids negtigible amounts of thrombin are
formed. Thus a possible source of error is excluded.
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Pipette into a plastic semi-micro cuvette: concentratlon ln assay
mlxture
Tris buffer Q)
citrated plasma
RVV-X solution (J2)
CaCl, solution (a)
385 pl
15  p l
50 pl
50 pl
volume fraction 0.015
RVV-X 6mg/l
CaCl2 5 mmol/l
s2337
Tris
NaCl
albumin
EDTA
0.19 mmol/l
39 mmol/l
78.5 mol/l
0.39 mgll
8 mmol/l
incubate 60 s at 37"C
diluted 52337 solution (14)* 500 pl
monitor the increase in absorbance due to
4-nitroaniline production at 405 nm continuously
or at fixed time intervals (every 15 s) during
3 min.
r 100 ul solution (14) diluted with Tris buffer (3) to 500 pl; pre-warmed'
If the LA/LI is greater than 0.4 min-l, the samples must be appropriately diluted
with buffer (3).
Standardcurve:constructastandardcurvebyplotting LA/Ltinmin-lobtainedwith
dilutions of the standard plasma against their concentrations expressed as 9o of
standard plasma.
Calculation: the results are expressed as percentage factor X relative to a standard
plasma. Therefore, the reaction velocity obtained with the sample must be compared
to velocities obtained with a series of dilutions of standard plasma.
Measurement: factor VII [1, 15, 16]
In principle, both factor VII and tissue thromboplastins can be determined through
their activating action on factor X; the experimental design must be such that the
factor of interest becomes rate-limiting. The principle of the factor VII determination
described below is as follows: factor VII in plasma is converted into factor VIlu by
trace amounts of factor Xu in the presence of thromboplastin and Ca'*. The activity
of factor VII" is measured by determinatiorr of the initital rate of factor X activation,
in the presence of thromboplastin and Ca'- -
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Pipette into a plastic semi-micro cuvette: concentratlon ln assay
mlxture
Tris buffer (2)
plasma (diluted 1 : 100 with
Tris buffer (2))
tissue thromboplastin
factor Xu solution (17)
CaCl2 solution (4)
110 p l
40 pl
10 pl
2O pl
201t1.
volume fraction
F X u
CaCl2
F X
0.04*
0.02 nmol/l
2mmol/l
0 .1pmol / l
Tris
NaCl
albumin
EDTA
s2337
44mmol/l
87 mol/l
0.44 s/l
14 mmol/l
0.19mmol/ l
incubate 5 min at 37'C
factor X solution (18b) l0  p l
incubate exactly 4 min at 37 " C
Tris buffer (3)
52337 solution (14)
700pl
100 pl
monitor the increase in absorbance due to
4-nitroaniline production at 405 nm continuously
or at fixed time intervals (every 15 s) during 3
min.
* 0.04 x 10 2 calculated on undiluted plasma.
rf LA/Lt is greater than 0.4 min-1, the samples must be appropriately diluted with
buffer (2).
Standard curve: construct a standard curve by plotting LA/Lt in min - 1 obtained with
dilutions'of the standard plasma against their concentrations expressed as go of
standard plasma.
Calculation: the results are expressed as percentage of factor VII relative to a standard
plasma. Therefore, the reaction velocity obtained with the sample must be compared
to velocities obtained with a series of dilutions of standard plasma.
Measurement: factor VIII
A substrate specific for factor X can be used to monitor the velocity of factor X"
formation from a known amount of factor X and hence to assess the activity of thJ
tenase complex (: factor X activating complex consisting of factor VIII., factor IXu,
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phospholipids and Ca2+). If factor IXu is present in a fixed and relatively high concen-
tration, then, in the presence of a fixed amount of phospholipid and Ca2*, factor
VIII' (produced by the activation of factor VIII by thrombin) becomes the rate-deter-
mining reaction constituent.
Factor VIIIo generation
Generation of factor X actiuoting complex, factor Xo(fuctor VIIIorate-limiting)
Pipette into a plastic tube: concentration in incubation
mixture
sample (plasma)
Tris buffer Q)
40 pl
910 p l
volume fraction er : 0.04
Tris 48 mmol/l
NaCl 96 mmol/l
albumin 0.48 g/l
F IIa 4.5 nmol/lfactor Ilusolution (15) 50 pl
mix, incubate exactly 1 min at 37oC, use a
500 pl aliquot for further treatment of ihe
activated sample.
Pipette successively into a plastic tube: concentration in incubation
mixture
Tris buffer Q)
factor IXu solution (16)
phospholipid suspension (13)
CaCl2 solution (4)
350 pl
2O p,l
201tl
60 pl
Tris
NaCl
albumin
F IXa
PS
PC
CaCl2
F X
46mmol/l
92mmol/l
0.46 g/l
0.05 pmol/l
60mg/l
9mg/l
6mmol/l
0.5 pmol/l
volume fraction Qz : 0.5*
mix, equilibrate temperature at 37"C
factor X solution (18b)
activated sample
50 pl
500 pl
mix, incubate exactly 1 and2 min, use a 100 pl
aliquot for colour reaction of factor X".
t 0.02 calculated on the original sample.
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Photometry
Pipette successively into a plastic semi-micro
cuvette:
concentratlon ln assay
mlxture
Tris buffer (3)
52337 solution (14)
800 pl
100pl
Tris
NaCl
albumin
EDTA
s2337
45 mmol/l
89.2mmol/l
0.45 g/l
16mmol/ l
0.19 mmol/ l
volume fraction
F IXa
PS
PC
CaCl2
F X
Q r  :  0 ' 1 +
5 nmol/l
0.6mg/l
0.9 mg/l
0.6 mmol/l
50 nmol/l
mlx
factor X activation complex 100 pl
mix, monitor the increase in absorbance due to
4-nitroaniline production at 405 nm continuously
or at fixed time intervals (every 15 s) during
3 min.
* 0.002 calculated on the original sample.
If LA/Lt is greater than 0.4 min r, the samples must be appropriately diluted with
buffer (2).
Correct results by subtracting the blank value determined with Tris buffer (2)
instead of plasma.
Standard curve: construct a standard curve by plotting LA / Lt in min I obtained with
dilutions of the standard plasma against their concentrations, expressed as 9o of
standard plasma.
Calculation: the results are expressed as percentage of factor VIII relative to a
standard plasma. Therefore, the reaction velocity obtained with the sample must be
compared to velocities obtained with a series of dilutions of standard plasma.
Measurement: factor IX [171
A substrate specific for factor Xu can be used to monitor the velocity of factor Xu
formation from a known amount of factor X by a tenase complex (: factor X
activating complex consisting of factor IXu, phospholipids and Caz*) in which,
because of the experimental design, factor IXu is the rate-determining reaction con-
stituent. The factor IX assay described below involves the following steps:
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a) conversion of plasma factor IX to factor IXu by purified factor XIu,
b) incubation of factor IXu with factor X, phospholipids and Ca2+,
c) addition of EDTA to stop factor Xu formation by IX",
d) determination of the amount of factor X" present from the rate of hydrolysis of
s 2337.
Factor IXo generation
* 0.02 calculated on undiluted plasma.
Generstion of factor X octiuating complex, factor Xo (factor IX o rate limiting)
Pipette into a plastic tube: concentration in incubation
mixture
Tris buffer (2)
CaCl2 solution (4)
factor XIu solution (19)
plasma (diluted 1 : 10 in
Tris buffer (2))
90 pl
15  p l
15  p l
30 pl
Tris 45 mmol/l
NaCl 90 mmol/l
albumin 0.45 mg/l
CaCl2 lOmmol/ml
F XIa 23mg/l
volume fraction er : 0.2+
mix, incubate 25 min at37"C, use a 100 pl
aliquot of this activation mixture for further
treatment of activated sample.
Pipette successively into a plastic tube: concentration in incubation
mixture
Tris buffer (2\
factor X solution (18a)
phospholipidsuspension (13)
CaCl2 solution (4)
200 pl
100 pl
50 pl
50 pl
44mmol/l
88 mol/l
0.44 g/l
O.2pmol/l
30 mgll
45 mg/l
10mmol/ l
Tris
NaCl
albumin
F X
PS
PC
CaCl2
volume fraction Q z :  0 . 2 *
mix, equilibrate at 37oC
activated sample 100 pl
mix, incubate exactly 10 min at 37oC, use a
400 pl aliquot of this incubation mixture for
colour reaction of factor Xu.
* 0.04 calculated on original sample; 0.004 calculated on undiluted plasma
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Photometry
Pipette successively into a plastic semi-micro
cuvette:
concentration in assay
mlxture
Tris buffer (3)
factor X activation complex
52337 solution (14)
400 pl
400 pl
100 pl
Tris 42mmol/l
NaCl 84 mol/l
albumin 0.42m9/l
EDTA 8.9 mmol/l
volume fraction et : 0.44*
52337 0.21mmol/l
F X 0.02 pmol/l
PS 3mg/l
PC 5ms/l
CaCl2 1.1mmol/ l
mix, monitor the increase in absorbance due to
4-nitroaniline production at 405 nm continuously
or at fixed time intervals (every 15 s) during 3min.
| 0.018 calculated on original sample; 0.0018 calculated on undiluled plasma.
lf LA/LI is greater than 0.4 min-r, the samples must be appropriately diluted in
buffer.
Standard curve: construct a standard curve by plotting LA/Lt in min-r obtained with
dilutions of the standard plasma against their concentrations, expressed as 9o of
standard plasma.
Calculation: the results are expressed as percentage of factor IX relative to a standard
plasma. Therefore, the reaction velocity obtained with the sample must be compared
to velocities obtained with a series of dilutions of standard plasma.
Yalidation of Methods
Precision, accuracy, detection limit and sensitivity: given on p.374 for factors II and
V; the same for factors VII and X.
The relative standard deviations (RSD) of the chromogenic substrate assays based
on factor X" measurement are (in 9o) [17]:
Factor RSDasruy RSDtor. RSDbiol
VII
VIII
IX
X
5 . 1
6.9
5 . 1
3 .0
21.8
29.7
1 1 . 0
1 5 . 0
2 t . l
9 .7
14.8
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RsDassay relative standard deviation (standard deviation expressed as percentage of
the mean)
RSDrot. inter-individual relative standard deviation determined in 33 healthy normal
individuals
RSDbiol. biological variation determined from (RSD,or.)2 : (RSDu,,ur)2 + (RSDbiol.)2.
Sources of error: in principle, the same as given on pp. 374,375. The presence of
unspecific activities must be checked in control experiments in which all substances
occurring in the assay system are present, except the enzyme to be determined.
Furthermore, the enzyme reaction can be inhibited by the chromogenic substrate.
Therefore, assay standardization is of utmost importance.
If factor Xu has to be measured in intact plasma, the plasma (blood) must be mixed
with an excess of anti-antithrombin lll-directed immunoglobulins [12] immediately
upon venepuncture. This lengthens the survival time of factor Xu without abolishing
factor Xu inactivation altogether, possibly because of the presence of factor Xu inhibi-
tors other than antithrombin III or u2-macroglobulin (whose action will hardly be
observed because the uTmacroglobulin-factor Xu complex is still able to split small
synthet ic substrates).
If instead of Rassel/'s viper venom (RVV-X) thromboplastin and factor VII are
used as an activator, less factor Xu seems to be formed than with RVV-X. V/ith
thromboplastin as an activator, the amount of factor X" formed is linearly related to
the amount of plasma from standard samples only over a narrow concentration
range, and the coefficient of variation is larger than with the RVV-X method [18].
In the factor VII assays, total factor VII is determined on the basis of a complete
activation of this factor. However, in this respect several difficulties have not yet been
overcome. The problems arise primarily from the fact that factor VII is present in
plasma in two molecular forms, as single-chain and two-chain molecules. The single-
chain form seems to have a distinct species specificity with respect to thromboplastin,
whereas the two-chain form has not [19] . The two-chain form arises in certain plasmas
upon storage at 4"C.It has also been suggested that the two-chain form is indicative
of different forms of disease, such as metastases from carcinoma of the prostate and
generalized atherosclerosis. As yet there are no methods available to differentiate
between the two forms in a chromogenic substrate assay. On the other hand, if tissue
thromboplastins of different species have to be compared, the result of the test will
depend upon the relative amount of the two-chain form of factor VII present in the
reaction mixture.
Inter-laboratory differences in thromboplastin preparations also greatly hamper
standardization of the factor VII determination. A further complication may result
from the fact that factor Xu can activate factor VII. The effect of a chromogenic
substrate occupying the active site of factor X" on the interaction with factor VII
remains to be investigated.
The determination of the factors VIII and IX is based on the activation of factor X
by the tenase complex. Through manipulation of the experimental conditions, factor
VIII or factor IX can become the rate-limiting reaction component in this complex. In
this respect it must be stressed that the V and K^ values of the tenase complex are
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dependent upon the amount and composition of the lipids present, which makes
standardization in this respect of crucial importance.
Reference ranges
Factor Xois absent from normal plasma. A. factor Xu concentration in the cuvette of 1
nmol/l will cause a L,A/LI : 0.070 min-' at 405 nm.
The concentration of factor X in normal plasma is 180 nmol/l; 15 pl of normal
plasma will cause an increase in absorbance at 405 nm of about L'A/Lt : 0.200
mln '.
Factor VII concentration in normal plasma is 10 nmol/l; 40 pl of normal plasma,
diluted 1:100. will cause an increase in absorbance at 405 nm of about L'A/L'( :
0.065 min-1 in the test system described above.
Factor VIII concentration in normal plasma is 0.2 nmol/l; 40 pl of normal plasma will
cause an increase in absorbance of about LA/Lt : 0.050 min I after 2 min of factor
X activation.
Factor IX concentration in normal plasma is 70 nmol/l; 30 pl of normal plasma,
diluted 1 : 10, will cause an increase in absorbance at 405 nm of about LA/ Lt : 0.028
mln
3.2.2.3 Determination of Factors XI" and XI [1,20]
It has been reported recently by lwanaga et al.l1l and Kato et al.I20l that factor XIu
can be determined with the fluorigenic substrate BOC-Phe-Ser-Arg-MCA (MCA :
7-amino-4-methyl-coumarine), which is relatively specific for factor XIu. This assay
can be used also to measure factol Xl after activation with factor XII.. However, the
authors only described a test for the determination of factor XI in model systems con-
taining purified coagulation factorsi no adaptation for its use in the determination of
factor XI in plasma has been reported. As we have no experience with this assay, we
will only give a schematic description of the method but no further experimental
details.
Preparation of solutions
1. Tris buffer (Tris, 50 mmol/l; NaCl, 0.15 mol/l; bovine serum albumin, 0'1 mglml;
pH 8.0) :
dissolve 6.05 g tris (hydroxymethyl) aminomethane and 8.76 g NaCl in 900 ml
water; proceed further as described for solution (1) on page 368 but adjust the pH
to 8.0. Supplement this Tris buffer with 0.1 g bovine serum albumin per 1000 ml'
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2. Tris buffer (Tris, 20 mmol/l; NaCl, 0.15 mol/l; bovine serum albumin, 0.1 mglml;
pH 8.0):
dissolve 2.42 g tris (hydroxymethyl) aminomethane and 8.76 g NaCl in 900 ml
water; proceed further as described for solution (1) on page 368 but adjust the pH
to 8.0. Supplement this Tris buffer with 0.1 g bovine serum albumin per 1000 ml.
3. BOC-Phe-Ser-Arg-MCA (10 mmol/l in dimethylformamide):
dissolve 67 mg substrate in 10 ml dimethylformamide.
4. Factor XII. solution (78 pg/ml in Tris buffer (1)):
cf. Appendix or obtain commercially.
Assay conditions: fluorigenic substrate assays are carried out in glass cuvettes in a
fluorimeter with a thermostatted cuvette holder at 37'C. Pre-warm buffer to 37'C.
Excitation wavelength 380 nm; emission wavelength 440 nm.
Measurement: fâctor XIa [1,20]
Standard curve: construct a standard curve by plotting the fluorescence increase per
min of dilutions of the factor XIu standard against their concentrations, analogously
to the photometric determinations.
Calculation: read the concentration of the sample from the standard curve as for the
photometric determination, p. 384.
Pipette into a glass cuvette: concentratlon ln assay
mixture
Tris buffer (1)
sample (containing approx. 10 pg
factor XIu)
500 pl
10  p l
Tris
NaCl
albumin
F XIu
48.5 mmol/l
145.6 mmol/l
0.r  g/ l
19.4mg/l
BOC-Phe-Ser-Arg-MCA
0.097 mmol/l
mix, incubate 5 min at 37 aC
BOC-Phe-Ser-Arg-MCA
solution (3) 5 rrl
mix. monitor the initial rate of the increase of
the relative fluorescence continuously or at fixed
time intervals during 10 min (excitation at
380nm. emission at 440 nm).
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Pipette into a glass tube: concentration in incubation
mixture
sample (containing approx.
500 pg factor Xllml)
Tris buffer (2)
factor XII. solution (4)
10 pl
600 pl
201tl
volume fraction er : 0.016
F XIIa 2.48mg/l
Tris 19.7 mmol/l
NaCl 147.6mmol/l
albumin 0.1g/ l
mix, incubate 30 min at 37"C; use a 10 pl
aliquot for fluorimetry.
Measurement: factor XI [1, 20]
Fuctor XIo generotion
Fluorimetry
* 0.0003 calculated on the original sample.
Standard curve: construct a standard curve by plotting the fluorescence increase per
min of dilutions of the factor XI standard against their concentrations, analogously to
the photometric determinations.
Calculation: read the concentration of the sample from the standard curve as for the
photometric determination, p. 384.
Pipette successively into a glass cuvette: concentratlon ln assay
mixture
Tris buffer (1)
activated sample
500 pl
10  p l
Tris 48.9 mmol/l
NaCl 148.5 mmol/l
albumin 0.19/l
volume fraction ez : 0.019*
BOC-Phe-Ser-Arg-MCA
0.097 mmol/l
mix. incubate 5 min at37"C
BOC-Phe-Ser-Arg-MCA
solution (3) 5 trl
mix, monitor the initial rate of the increase of
the relative fluorescence continuously or at fixed
time intervals during 10 min (excitation at
380 nm. emission at 440 nm).
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Validation of Methods
The authors stated that the substrate BOC-Phe-Ser-Arg-MCA is very susceptible to
cleavage by trypsin: therefore, soybean trypsin inhibitor (SBTD should be added to
the reaction mixture if trypsin can be expected to be present in the sample. They
further reported that the hydrolysis rate is constant over a period up to 10 minutes and
that proportionality between the amount of enzyme used and the activity measured is
observed over a lGfold range. Factor XIu activity is quantitatively measured up to a
concentration of 0.5 p"g/ml. Moreover, the sensitivity of the measurement of the
fluorescence increase due to AMC release can be amplified 10 times, depending on the
instrument used; therefore, the limit of detection of factor XIu is 50 nmol/I.
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Appendix
Purification of coagulation factors and preparation of reagents for chromogenic sub-
strate assays.
Gerbrand van Dieijen and Truus Janssen-Claessen
The purification procedures described here are currently used in the Department of
Biochemistry in Maastricht and are adapted from several publications, mainly from
the laboratories of E. Dsuie, Seattle WA; C. M. Jackson, St. Louis, MO and
Y. Nemerson, New York, NY [1, 2] .
Preporotion of bovine prothrombin, factor X and factor IX [3 - 5J
At the slaughterhouse collect 50 I ox blood using a mixture of citrate and inhibitors as
anticoagulant. Mix 9 I blood with 1 I of a solution containing: 36 g sodium citrate;
7.2 gbenzamidine; 10 ml trasylol (100000 KI[I); 0.0 g heparin (100000 U/l). Centri-
fuge the blood for 30 min at 25m rpm in the MSE Mistral centrifuge with the 6 x 1
litre rotor. Aspirate the plasma from the red cells and add 80 ml BaCl2, 1 mol,/I, to the
plasma solution. Stir the suspension for 60 min at 4'C. Collect the barium-citrate
pellet by centrifugation (10 min; 2500 rpm) and wash the sediment wice (150 ml
buffer per litre plasma) with buffer containing per litre: 9 g NaCl; benzamidine,
lOmmol; BaCI2, 5 mmol; 10 mg soybean trypsin inhibitor (SBTD. Elute proteins
from Ba-citrate with 2 | of a buffer containing: Na-citrate, 0.2 mol/l; benzamidine,
10 mmol/l; soybean trypsin inhibitor, 40 mg/l;2 ampoules trasylol (200000 KILD;
pH 6.9 adjusted with citric acid, 1 mol/I. Add solid (NH4)2SO4 to the eluate to achieve
3590 saturation. The precipitate is discarded and the supernatant is brought to 6590
(NH4)2SO4 saturation. Collect precipitates by centrifugation (30 min, 12000 rpm,
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JA-14 Rotor , Beckmon). Dissolve the final 6590 (NHa)2SO+ precipitate in 50- 75 ml
of a buffer consisting of morpholino ethanesulphonic acid (MES)/NaOH, 20 mmol/I,
and benzamidine, 1 mmol/l; pH 6.0. Dialyze the protein solution against two 1 I
changes of the same buffer and adsorb the protein onto a DEAE-Sephadex column
(2.5 x 35 cm), equilibrated with MES/NaOH (pu 6.0) buffer. Wash the column with
300 ml MES/NaOH buffer containing NaCl, 0.15 mol/I, and elute with a NaCl gra-
dient (2 x 500 ml), ranging from 0.15 to 0.6 mol/l in MES/NaOH, 20 mmol/I, benz-
amidine, 1 mmol/l (ps 6.0).
The first strongly adsorbing fraction of the eluate from the DEAE-column contains
prothrombin, factor IX and factor VII, and the weakly adsorbing fraction at the end
of the gradient contains factors X1 and X2. Make two protein pools, the first contain-
ing prothrombin and factors VII and IX, the second pool containing factors X1 and
x2.
Separate factor X1 and X2 by the method of Fuiikawa et al.I4l. Adsorb the proteins
to a DEAE-Sephadex column (2.5 x 30 cm) and use a gradient (2 x l litre) of sodium
citrate from 0.1 mol/l to 0.2 mol/\, pH 6.9, containing benzamidine, 10 mmol/I, to
elute the column. Pool fractions containing factor X1 and fractions containing factor
X2 separately, concentrate by ultrafiltration (Amicon PM 10) and dialyze extensively
against Tris/HCl buffer (50 mmol/l; NaCl, 0.1 mol/l; pH 7.8).
Dialyze the pooled fractions from the DEAE-column containing prothrombin,
factor IX and factor VII and adsorb to a heparin-agarose column (2.2 X 20 cm) using
a buffer containing: imidazol, 50 mmol/l; benzamidine, 1 mmol/l; CaCl2, 2.5
mmol/l; pH 6.0. Elute prothrombin and factor VII stepwise using imidazol buffer
(50 mol/l) containing NaCl, 0.15 mol/l respectively 0.25 mol/I.
Elute factor IX with a salt gradient (NaCl, 2 x 300 ml) in imidazol buffer ranging
from 0.25 to 0.7 mol/l [5]. Pool the prothrombin-containing fractions, concentrate
and fractionate using a Sephadex-G100 column (2.5 x 90 cm). Fractionate factor lX
under the same conditions.
The prothrombin, factor IX and factor X1 and X2 preparations were apparently
pure as judged by SDS-gel electrophoresis. The specific activities determined in a
clotting assay were 4 units/mg for prothrombin, 100 units/mg for factors X1 and X2,
and 145 units/mg for factor IX, assuming the presence of 1 unit of each of the factors
in normal bovine plasma.
Factor XIo preparation
Isolate the factor XIu preparation from "bovine contact product" prepared according
to Nosse/ [6] and further purify this preparation by heparin/agarose affinity chroma-
tography as suggested by @sterud et al. l7l. To obtain "bovine contact product" stir
the supernatant obtained after Ba-citrate adsorption of bovine plasma (see above)
with Celite (535 Johns Monaille),50 g/l plasma, during 45 min at room temperature.
Wash the Celite 4-5 times with a buffer containing: Tris/HCl,20 mmol/l;0.990
NaCl; pH 7.0 (llitre/ 1009 Celite). Elute contact product from Celite with buffer
containing: Tris/HCl, 20 mmol/l; NaCI, 2 mol/l; pH 7.0.
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Concentrate the eluate and dialyze against sodium acetate buffer, 50 mmol/I,
pH 5.5. Adsorb crude contact product to a heparin-agarose column (1.5 x 20 cm) [7] ,
wash the column with 250 ml of a buffer containing sodium acetate, 50 mmol/l;
NaCl, 0.3 mol/l; pH 5.5 and elute subsequently with a salt gradient (NaCl, 2 x 250 ml)
from 0.3 mol/l to 1.0 mmol/l in the same buffer. Pool fractions containing factor
XIu, identified by a clotting assay using factor Xl-deficient plasma, concentrate in an
Amicon cell and dialyze against a buffer containing: Tris/HCl, 50 mmol/l; NaCl, 0.1
mol/l; pu 7.8. Determine the concentration from absorbance, assuming that one,4æs
unit/ml is equivalent to 1 mg protein per ml.
Thrombin preparation [8J
Incubate 10 mg prothrombin and25 pg factor X" overnight at 37 oC in a reaction
mixture of 5 ml containing: Tris/HCl, 50 mmol/l; NaCl, 0.1 mol/l; CaCl2,
20mmol/l; pH 7.8. After incubation remove the precipitate and dialyzc the protein
against a sodium phosphate buffer, 50 mmol,/I, pH 8.5. Adsorb the protein to a
SP-Sephadex column (1.5 x 15 cm) [8]. Wash the column with 150 ml phosphate
buffer containing NaCl,0.15 mol/|, and develop with a NaCl gradient (2x 200 ml)
from 0.15 to 0.45 mol/l in sodium phosphate buffer, 50 mmol/I, pH 6.5. Pool the
thrombin containing fractions, concentrate and dialyze against Tris/HCl buffer,
50 mmol/l; NaCl, 0.1 mol/l; pu 7.8.
Factor Xo preparation [9J
Prepare bovine factor X" by activation of factor Xby Russell's viper venom [9] .
Incubate 2 mg factor X and 0.1 mg RVV in 2 ml Tris/HCl buffer, 50 mmol/l; NaCl,
0.1 mol/l and CaCl2, 10 mmol/l; pu 7.8. Follow the activation by transferring
aliquots from the reaction mixture to a cuvette containing S 2337. When a plateau
level of activation is reached, add EDTA to a final concentration of 20 mmol/I, and
dialyze the reaction mixture against a buffer containing: Tris/HCl, 50 mmol/l;
citrate,60 mmol/l; pH7.7. After dialysis adsorb the proteins of the sample onto a
DEAE-Sephadex column (1.5 x 15 cm) equilibrated with a buffer containing Tris,
50 mmol/I, and citrate, 0.1 mol/l; pH 8.0.
Elute the column with a NaCl gradient (2 x 150 ml) from 0 - 0.6 mol/l in a buffer
containing: Tris, 50 mmol/l; citrate,0.1 mol/l; pH 8.0. Pool fractions containing
factor Xu (identified with S 2337 as substrate) and dialyze against Tris/HCl buffer,
50 mmol/l; NaCl, 0.1 mol/l; pH 7.8.
Foctor IX o preporation I I 0J
Incubate 10 mg factor IX and 0.2 mg factor XI" in a reaction volume of 5 ml for
90 min at 37 " C in Tris/HCl buffer, 50 mmol/l; NaCl, 50 mmol/l; CaCl2,10 mmol/l;
pu 8.5. After 90 min the activation is complete. Add EDTA (ps 7.5) to a final con-
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centration of 30 mmol/l. Adsorb the proteins of the mixture onto a DEAE-Sephadex
column (1 x 13 cm) equilibrated with Tris/HCl buffer, 0.15 mol/l; NaCl, 50 mmol/l;
benzamidine, 20 mmol/l; Pe.7.9'
wash the column with 200 ml of the same buffer containing Nacl, 0.1 mol/l and
elute with a NaCl gradient (2 x 150 ml) from 0.1 to 0.4 mol/l in the same buffer. Pool
factor IXu fractions, identified by a clotting assay in absence of kaolin using a IX;
deficient reagent, concentrate and dialyze against Tris/HCl buffer, 50 mmol/l; NaCl'
0 .1 mol / l ;  pu 8.
Dialyze ihe protein preparations against a Tris/HCl buffer, 50 mmol/l; NaCl,
0.1 mol / l ;  pH 7.8.
Estimation of protein concentrstion of prothrombin, factor X 1 and X2 and factor IX
Estimate the protein concentrations from absorbance at 280 nm using ,41e values of
15.5 for prothrombin 131,12.4 for factor X1 and X2 [4] and 74'9 for factor IX [5]. The
moleculâr weights used to calculate molar concentrations are: 72000 for prothrombin,
55000 for factor X1 and X2 and factor IX.
Determine the concentrations of thrombin' factor Xu and factor IXu by active-site
titration or calculate from absorbance using,44e values of 20.0 for thrombin , t2'4 for
factor Xu and 14.3 for factor IXa [3 , 8, 9] . The molecular weights used are 36 000 for
thrombin and 44000 for factors Xu and IXu.
Actitte-site titration of thrombin, fsctor Xo, and foctor IXo Il ] - I3l
All coagulation factors are diluted to the desired concentration in a buffer containing
Tris. 50 mmol/l; NaCl, 100 mmol/l; p+l.9, and albumin, 0.5 mglml. The factors are
frozen and stored in small aliquots at - 70oC'
Dialyz,e the proteins against sodium barbital buffer, 50 mmol/l, pH 8.3' Place
thermostatted cuvettes in a double-beam spectrophotometer, set wavelength at
405 nm. Typically, the sample cuvette contains 40-2OO pg of protein in 800 pl
barbital buffer, 50 mmol/l; CaCl2,20 mmol/I. The reference cuvette contains calcium
barbital but no protein. After 5 min equilibration add 5 pl4-nitrophenyl4'-guanidino-
benzoate solution, 20 mol/\. A rapid increase \n Aas5 absorbance ("burst") is
observed. After 2-3 min (for factor IXu) no further or a small constant increase is
observed. Determine the burst by extrapolation to time zero. Calculate the molar
protein concentration from the burst using a millimolar absorption coefficient for
4-nitrophenol at 405 nm of 1.84 I X mmol 
- 1 X mm 1, and assuming the liberation of
I mol of 4-nitrophenol per môl enzyme protein.
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3.2.3 Blood Coagulation Factor XII
Hageman Factor
Cornelis Kluft. Petronella Los and Lars Svendsen
General
The proteolytic enzyme factor XIIa is present in mammalian plasma in an inactive
form, factor XII or Hagemon factor. The factor was identifiedby Ratnoff & Colopy
in 1955 because of its congenital absence from Mr. Hagemon's blood [1]. Later, it was
isolated from blood and characterized12).
The activation of factor XII is triggered by negatively-charged surfaces such as
glass, kaolin or silica, or negatively-charged soluble polymers such as dextran sul-
phate. In addition it requires the participation of the plasma factors prekallikrein and
high molecular weight kininogen [3]. Factor XII participates in the first step of the
intrinsic pathway of coagulation and in various other processes such as fibrinolysis,
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